{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-003013","form_type":"8-K","ticker":"OTLK","cik":"0001649989","company_name":"Outlook Therapeutics, Inc.","filed_at":"2025-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.307964+00:00","generated_at":"2026-05-24T18:34:19.396591+00:00","sec_items":["1.02","5.03","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Outlook Therapeutics closes $33.1M convertible note, increases authorized shares to 260M","bullets":["Issued $33.1M convertible note to Avondale Capital on March 13, 2025; proceeds used to repay $32.91M Streeterville note.","Stockholders approved increase in authorized common shares from 60M to 260M, effective March 11.","Annual Meeting elected directors: Julian Gangolli, Ralph Thurman, Lawrence Kenyon to Class III.","Stockholders approved potential issuance of >19.99% of outstanding common stock upon note conversion.","Ratified KPMG as auditor for FY2025; advisory say-on-pay passed."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-003013","json":"https://secwatch.observer/filing/0001558370-25-003013.json","markdown":"https://secwatch.observer/filing/0001558370-25-003013.md","text":"https://secwatch.observer/filing/0001558370-25-003013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/0001558370-25-003013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1649989/000155837025003013/otlk-20250311x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T18:34:19.396591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}